Peringatan Keamanan

Almost twice as many people discontinued rimonabant compared with placebo because of adverse events (13.8% vs. 7.2%). These consistently involved psychiatric disorders (8.5% vs. 3.2%), including depression and anxiety. Other common side effects included insomnia, nausea, vomiting, diarrhoea and fatigue.

Rimonabant

DB06155

small molecule approved investigational

Deskripsi

Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States. This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression.

Struktur Molekul 2D

Berat 463.787
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 6 to 9 days with normal BMI and 16 days if BMI is greater than 30
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Undetermined

Metabolisme

Hepatic, CYP3A4 involved.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

922 Data
Cocaine Cocaine may increase the tachycardic activities of Rimonabant.
Trospium The risk or severity of Tachycardia and drowsiness can be increased when Trospium is combined with Rimonabant.
Oxyphenonium The risk or severity of Tachycardia and drowsiness can be increased when Oxyphenonium is combined with Rimonabant.
Benzatropine The risk or severity of Tachycardia and drowsiness can be increased when Benzatropine is combined with Rimonabant.
Disopyramide The risk or severity of Tachycardia and drowsiness can be increased when Disopyramide is combined with Rimonabant.
Ipratropium The risk or severity of Tachycardia and drowsiness can be increased when Ipratropium is combined with Rimonabant.
Metixene The risk or severity of Tachycardia and drowsiness can be increased when Metixene is combined with Rimonabant.
Buclizine The risk or severity of Tachycardia and drowsiness can be increased when Buclizine is combined with Rimonabant.
Trihexyphenidyl The risk or severity of Tachycardia and drowsiness can be increased when Trihexyphenidyl is combined with Rimonabant.
Oxyphencyclimine The risk or severity of Tachycardia and drowsiness can be increased when Oxyphencyclimine is combined with Rimonabant.
Procyclidine The risk or severity of Tachycardia and drowsiness can be increased when Procyclidine is combined with Rimonabant.
Profenamine The risk or severity of Tachycardia and drowsiness can be increased when Profenamine is combined with Rimonabant.
Hyoscyamine The risk or severity of Tachycardia and drowsiness can be increased when Hyoscyamine is combined with Rimonabant.
Methscopolamine bromide The risk or severity of Tachycardia and drowsiness can be increased when Methscopolamine bromide is combined with Rimonabant.
Tridihexethyl The risk or severity of Tachycardia and drowsiness can be increased when Tridihexethyl is combined with Rimonabant.
Anisotropine methylbromide The risk or severity of Tachycardia and drowsiness can be increased when Anisotropine methylbromide is combined with Rimonabant.
Atropine The risk or severity of Tachycardia and drowsiness can be increased when Atropine is combined with Rimonabant.
Nicardipine The risk or severity of Tachycardia and drowsiness can be increased when Nicardipine is combined with Rimonabant.
Pirenzepine The risk or severity of Tachycardia and drowsiness can be increased when Pirenzepine is combined with Rimonabant.
Homatropine methylbromide The risk or severity of Tachycardia and drowsiness can be increased when Homatropine methylbromide is combined with Rimonabant.
Benzquinamide The risk or severity of Tachycardia and drowsiness can be increased when Benzquinamide is combined with Rimonabant.
Propantheline The risk or severity of Tachycardia and drowsiness can be increased when Propantheline is combined with Rimonabant.
Dicyclomine The risk or severity of Tachycardia and drowsiness can be increased when Dicyclomine is combined with Rimonabant.
Biperiden The risk or severity of Tachycardia and drowsiness can be increased when Biperiden is combined with Rimonabant.
Methantheline The risk or severity of Tachycardia and drowsiness can be increased when Methantheline is combined with Rimonabant.
Cycrimine The risk or severity of Tachycardia and drowsiness can be increased when Cycrimine is combined with Rimonabant.
Glycopyrronium The risk or severity of Tachycardia and drowsiness can be increased when Glycopyrronium is combined with Rimonabant.
Tolterodine The risk or severity of Tachycardia and drowsiness can be increased when Tolterodine is combined with Rimonabant.
Oxybutynin The risk or severity of Tachycardia and drowsiness can be increased when Oxybutynin is combined with Rimonabant.
Flavoxate The risk or severity of Tachycardia and drowsiness can be increased when Flavoxate is combined with Rimonabant.
Diphenidol The risk or severity of Tachycardia and drowsiness can be increased when Diphenidol is combined with Rimonabant.
Tiotropium The risk or severity of Tachycardia and drowsiness can be increased when Tiotropium is combined with Rimonabant.
Solifenacin The risk or severity of Tachycardia and drowsiness can be increased when Solifenacin is combined with Rimonabant.
Isopropamide The risk or severity of Tachycardia and drowsiness can be increased when Isopropamide is combined with Rimonabant.
Mepenzolate The risk or severity of Tachycardia and drowsiness can be increased when Mepenzolate is combined with Rimonabant.
Fesoterodine The risk or severity of Tachycardia and drowsiness can be increased when Fesoterodine is combined with Rimonabant.
Hexocyclium The risk or severity of Tachycardia and drowsiness can be increased when Hexocyclium is combined with Rimonabant.
Dimetindene The risk or severity of Tachycardia and drowsiness can be increased when Dimetindene is combined with Rimonabant.
Aclidinium The risk or severity of Tachycardia and drowsiness can be increased when Aclidinium is combined with Rimonabant.
Dexetimide The risk or severity of Tachycardia and drowsiness can be increased when Dexetimide is combined with Rimonabant.
Umeclidinium The risk or severity of Tachycardia and drowsiness can be increased when Umeclidinium is combined with Rimonabant.
Trimebutine The risk or severity of Tachycardia and drowsiness can be increased when Trimebutine is combined with Rimonabant.
Imidafenacin The risk or severity of Tachycardia and drowsiness can be increased when Imidafenacin is combined with Rimonabant.
Butylscopolamine The risk or severity of Tachycardia and drowsiness can be increased when Butylscopolamine is combined with Rimonabant.
Thonzylamine The risk or severity of Tachycardia and drowsiness can be increased when Thonzylamine is combined with Rimonabant.
Methscopolamine The risk or severity of Tachycardia and drowsiness can be increased when Methscopolamine is combined with Rimonabant.
Revefenacin The risk or severity of Tachycardia and drowsiness can be increased when Revefenacin is combined with Rimonabant.
Oxitropium The risk or severity of Tachycardia and drowsiness can be increased when Oxitropium is combined with Rimonabant.
Propiverine The risk or severity of Tachycardia and drowsiness can be increased when Propiverine is combined with Rimonabant.
Batefenterol The risk or severity of Tachycardia and drowsiness can be increased when Batefenterol is combined with Rimonabant.
Mebeverine The risk or severity of Tachycardia and drowsiness can be increased when Mebeverine is combined with Rimonabant.
Tropatepine The risk or severity of Tachycardia and drowsiness can be increased when Tropatepine is combined with Rimonabant.
Prifinium The risk or severity of Tachycardia and drowsiness can be increased when Prifinium is combined with Rimonabant.
Piperidolate The risk or severity of Tachycardia and drowsiness can be increased when Piperidolate is combined with Rimonabant.
Benzilone The risk or severity of Tachycardia and drowsiness can be increased when Benzilone is combined with Rimonabant.
Difemerine The risk or severity of Tachycardia and drowsiness can be increased when Difemerine is combined with Rimonabant.
Phenglutarimide The risk or severity of Tachycardia and drowsiness can be increased when Phenglutarimide is combined with Rimonabant.
Mazaticol The risk or severity of Tachycardia and drowsiness can be increased when Mazaticol is combined with Rimonabant.
Etybenzatropine The risk or severity of Tachycardia and drowsiness can be increased when Etybenzatropine is combined with Rimonabant.
Otilonium The risk or severity of Tachycardia and drowsiness can be increased when Otilonium is combined with Rimonabant.
Poldine The risk or severity of Tachycardia and drowsiness can be increased when Poldine is combined with Rimonabant.
Bevonium The risk or severity of Tachycardia and drowsiness can be increased when Bevonium is combined with Rimonabant.
Rociverine The risk or severity of Tachycardia and drowsiness can be increased when Rociverine is combined with Rimonabant.
Bornaprine The risk or severity of Tachycardia and drowsiness can be increased when Bornaprine is combined with Rimonabant.
Etanautine The risk or severity of Tachycardia and drowsiness can be increased when Etanautine is combined with Rimonabant.
Tiemonium iodide The risk or severity of Tachycardia and drowsiness can be increased when Tiemonium iodide is combined with Rimonabant.
Dihexyverine The risk or severity of Tachycardia and drowsiness can be increased when Dihexyverine is combined with Rimonabant.
Penthienate The risk or severity of Tachycardia and drowsiness can be increased when Penthienate is combined with Rimonabant.
Diphemanil The risk or severity of Tachycardia and drowsiness can be increased when Diphemanil is combined with Rimonabant.
Camylofin The risk or severity of Tachycardia and drowsiness can be increased when Camylofin is combined with Rimonabant.
Fenpiverinium The risk or severity of Tachycardia and drowsiness can be increased when Fenpiverinium is combined with Rimonabant.
Emetonium iodide The risk or severity of Tachycardia and drowsiness can be increased when Emetonium iodide is combined with Rimonabant.
Pipenzolate The risk or severity of Tachycardia and drowsiness can be increased when Pipenzolate is combined with Rimonabant.
Timepidium The risk or severity of Tachycardia and drowsiness can be increased when Timepidium is combined with Rimonabant.
Darifenacin The risk or severity of Tachycardia and drowsiness can be increased when Darifenacin is combined with Rimonabant.
Quinidine The risk or severity of Tachycardia and drowsiness can be increased when Quinidine is combined with Rimonabant.
Chlorphenoxamine The risk or severity of Tachycardia and drowsiness can be increased when Chlorphenoxamine is combined with Rimonabant.
Midodrine The risk or severity of Tachycardia can be increased when Rimonabant is combined with Midodrine.
Norepinephrine The risk or severity of Tachycardia can be increased when Rimonabant is combined with Norepinephrine.
Phenylephrine The risk or severity of Tachycardia can be increased when Rimonabant is combined with Phenylephrine.
Phenylpropanolamine The risk or severity of Tachycardia can be increased when Rimonabant is combined with Phenylpropanolamine.
Labetalol The risk or severity of Tachycardia can be increased when Rimonabant is combined with Labetalol.
Metaraminol The risk or severity of Tachycardia can be increased when Rimonabant is combined with Metaraminol.
Methoxamine The risk or severity of Tachycardia can be increased when Rimonabant is combined with Methoxamine.
Orciprenaline The risk or severity of Tachycardia can be increased when Rimonabant is combined with Orciprenaline.
Phenmetrazine The risk or severity of Tachycardia can be increased when Rimonabant is combined with Phenmetrazine.
Dobutamine The risk or severity of Tachycardia can be increased when Rimonabant is combined with Dobutamine.
Pseudoephedrine The risk or severity of Tachycardia can be increased when Rimonabant is combined with Pseudoephedrine.
Ritodrine The risk or severity of Tachycardia can be increased when Rimonabant is combined with Ritodrine.
Terbutaline The risk or severity of Tachycardia can be increased when Rimonabant is combined with Terbutaline.
Oxymetazoline The risk or severity of Tachycardia can be increased when Rimonabant is combined with Oxymetazoline.
Dopamine The risk or severity of Tachycardia can be increased when Rimonabant is combined with Dopamine.
Isoprenaline The risk or severity of Tachycardia can be increased when Rimonabant is combined with Isoprenaline.
Acebutolol The risk or severity of Tachycardia can be increased when Rimonabant is combined with Acebutolol.
Lisdexamfetamine The risk or severity of Tachycardia can be increased when Rimonabant is combined with Lisdexamfetamine.
Fenoterol The risk or severity of Tachycardia can be increased when Rimonabant is combined with Fenoterol.
Ephedrine The risk or severity of Tachycardia can be increased when Rimonabant is combined with Ephedrine.
Mephentermine The risk or severity of Tachycardia can be increased when Rimonabant is combined with Mephentermine.
Procaterol The risk or severity of Tachycardia can be increased when Rimonabant is combined with Procaterol.
Clenbuterol The risk or severity of Tachycardia can be increased when Rimonabant is combined with Clenbuterol.

Target Protein

Cannabinoid receptor 1 CNR1
G-protein coupled receptor 55 GPR55

Referensi & Sumber

Synthesis reference: Alain Alcade, Gilles Anne-Archard, Corinne Gavory, Olivier Monnier, "Polymorphic form of rimonabant method for preparing it and pharmaceutical compositions containing it." U.S. Patent US20050043356, issued February 24, 2005.
Artikel (PubMed)
  • PMID: 16503766
    Gelfand EV, Cannon CP: Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin Investig Drugs. 2006 Mar;15(3):307-15.
  • PMID: 17489873
    Xie S, Furjanic MA, Ferrara JJ, McAndrew NR, Ardino EL, Ngondara A, Bernstein Y, Thomas KJ, Kim E, Walker JM, Nagar S, Ward SJ, Raffa RB: The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use. J Clin Pharm Ther. 2007 Jun;32(3):209-31.
  • PMID: 17943852
    Cahill K, Ussher M: Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005353.
  • PMID: 16483675
    Maldonado R, Valverde O, Berrendero F: Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 2006 Apr;29(4):225-32. Epub 2006 Feb 17.
  • PMID: 17762525
    Deadwyler SA, Goonawardena AV, Hampson RE: Short-term memory is modulated by the spontaneous release of endocannabinoids: evidence from hippocampal population codes. Behav Pharmacol. 2007 Sep;18(5-6):571-80.
  • PMID: 11296091
    Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Frank RA: Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry. 2001 Apr;58(4):322-8.

Contoh Produk & Brand

Produk: 22 • International brands: 3
Produk
  • Acomplia
    Tablet, film coated • 20 mg • Oral • EU
  • Acomplia
    Tablet, film coated • 20 mg • Oral • EU
  • Acomplia
    Tablet, film coated • 20 mg • Oral • EU
  • Acomplia
    Tablet, film coated • 20 mg • Oral • EU
  • Acomplia
    Tablet, film coated • 20 mg • Oral • EU
  • Acomplia
    Tablet, film coated • 20 mg • Oral • EU
  • Acomplia
    Tablet, film coated • 20 mg • Oral • EU
  • Acomplia
    Tablet, film coated • 20 mg • Oral • EU
Menampilkan 8 dari 22 produk.
International Brands
  • Rimoslim
  • Riobant — SUN
  • Slimona

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul